Tirzepatide: Mechanism, Research & UK Safety Profile
Also known as: LY3298176, Mounjaro, Zepbound
A dual GIP and GLP-1 receptor agonist developed by Eli Lilly, demonstrating unprecedented mean body-weight reductions of approximately 22% in the landmark SURMOUNT-1 trial at 72 weeks.
Molecular formula
C₂₂₅H₳₄₈N₄₀O₆₈
Molecular weight
4813.5 Da
Half-life
Approximately 5 days (120 hours), supporting once-weekly dosing and enabling steady-state plasma concentrations within 4–5 weeks of initiation at any given dose step.
Category
GLP-1/GIP Agonists
Overview
Tirzepatide is a synthetic 39-amino acid peptide developed by Eli Lilly and Company that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual-incretin mechanism distinguishes tirzepatide from earlier GLP-1 monoagonists and underpins the substantially greater weight-loss and glycaemic-control effects observed in clinical trials.
The compound is marketed under the brand name Mounjaro for the management of type 2 diabetes and Zepbound for chronic weight management in the United States. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) granted approval for tirzepatide (Mounjaro) for the treatment of type 2 diabetes in November 2023 and subsequently for chronic weight management in adults with obesity or overweight with weight-related comorbidities. It is supplied as a prefilled autoinjector pen for once-weekly subcutaneous administration.
The SURMOUNT clinical programme demonstrated that tirzepatide produced mean body-weight reductions substantially greater than those previously observed with any approved pharmacological agent. In SURMOUNT-1—a 72-week randomised controlled trial in adults without diabetes—participants receiving the 15 mg maintenance dose achieved a mean weight reduction of approximately 22.5% from baseline, with a significant proportion achieving reductions exceeding 25%. These findings generated considerable scientific interest in the potential of dual incretin agonism as a research paradigm.
Beyond weight reduction, tirzepatide has demonstrated improvements across a broad range of cardiometabolic parameters including fasting plasma glucose, HbA1c, systolic blood pressure, triglycerides, and waist circumference. The SELECT cardiovascular outcomes programme and subsequent SURPASS cardiovascular data have further characterised the compound's effects on hard cardiovascular endpoints. Its combination of efficacy depth and once-weekly convenience has positioned tirzepatide as a reference compound in the evolving landscape of metabolic peptide research.
For research purposes, tirzepatide serves as an important pharmacological tool for investigating the relative contributions of GIP and GLP-1 receptor signalling to metabolic regulation, adipose tissue biology, and neuroendocrine appetite control. The compound's profile continues to be characterised in ongoing trials investigating applications in heart failure, sleep apnoea, and non-alcoholic steatohepatitis (NASH).
Discovery & Research History
Tirzepatide originated from Eli Lilly's incretin biology research programme, which had long explored the therapeutic potential of gut-derived hormones in metabolic disease. The scientific rationale for combining GIP and GLP-1 agonism emerged from observations that these two incretins exert complementary effects on insulin secretion, gastric emptying, and energy homeostasis, yet their receptors are expressed in distinct tissue distributions.
Early Eli Lilly research demonstrated that GIP receptor agonism, when combined with GLP-1 receptor activation, produced additive or synergistic effects on insulin secretion in preclinical models—effects that exceeded what either pathway could achieve alone. This mechanistic insight drove the development of a single peptide capable of activating both receptors with balanced potency, rather than co-administering two separate agents.
The molecular design of tirzepatide drew on the native GIP sequence as its structural scaffold, with selective modifications conferring GLP-1 receptor agonism and a C-18 fatty diacid moiety enabling albumin binding and extended half-life suitable for once-weekly dosing. This fatty acid conjugation strategy had previously been validated in Novo Nordisk's semaglutide programme, and Eli Lilly adapted and refined the approach for the dual-agonist context.
Phase 1 studies confirming tirzepatide's pharmacokinetic profile and tolerability were published in the early 2010s, followed by the SURPASS phase 3 programme (SURPASS-1 through SURPASS-5 and SURPASS-CVOT) investigating type 2 diabetes management, and the SURMOUNT programme (SURMOUNT-1 through SURMOUNT-4) investigating chronic weight management. Key SURMOUNT results were published in The New England Journal of Medicine in 2022, establishing tirzepatide as the most efficacious pharmacological weight-management agent in any published randomised controlled trial at that time.
Mechanism of Action
Tirzepatide achieves its metabolic effects through simultaneous engagement of two distinct incretin receptors, each coupled to overlapping but non-identical intracellular signalling networks:
GLP-1 Receptor Agonism
Glucagon-like peptide-1 is secreted by intestinal L-cells in response to nutrient ingestion. Tirzepatide activates GLP-1 receptors in pancreatic beta cells, stimulating glucose-dependent insulin secretion—an effect that self-limits at euglycaemia, reducing hypoglycaemia risk. In the central nervous system, GLP-1 receptor activation in the hypothalamus and brainstem suppresses appetite, prolongs satiety signalling, and reduces hedonic drive toward energy-dense foods. Gastric GLP-1 receptor activation delays gastric emptying, moderating postprandial glucose excursions.
GIP Receptor Agonism
Glucose-dependent insulinotropic polypeptide is secreted by intestinal K-cells and constitutes the dominant incretin in quantitative terms. GIP receptor activation amplifies insulin secretion synergistically with GLP-1 receptor signalling. Crucially, GIP receptors are expressed abundantly in adipose tissue, where agonism appears to promote energy storage partitioning and may modulate lipolysis in a depot-specific manner. In the central nervous system, GIP receptor expression in the hypothalamus and ventral tegmental area likely contributes to tirzepatide's appetite-suppressing and reward-attenuating effects.
Synergistic Dual-Receptor Signalling
Research in rodent models and human cell systems suggests that co-activation of GIP and GLP-1 receptors produces effects on cAMP generation, PKA signalling, and downstream transcriptional programmes that exceed simple additive expectations. The adipose GIP receptor axis may also sensitise adipose tissue to the lipolytic effects of GLP-1 receptor agonism, helping explain why tirzepatide produces greater fat-mass reduction than GLP-1 monoagonists at comparable doses.
Appetite and Energy Intake Reduction
Central nervous system effects of tirzepatide reduce ad libitum energy intake substantially—randomised mechanistic studies have quantified reductions of 500–800 kcal/day in research participants at maintenance doses. This is mediated through suppression of hunger and pre-meal appetite ratings as well as reduction in the rewarding salience of food cues, effects attributed to hypothalamic, mesolimbic, and brainstem receptor populations.
Gastric Emptying Modulation
Tirzepatide slows gastric emptying, blunting postprandial glucose and lipid absorption kinetics. This effect is most pronounced early in treatment and undergoes partial attenuation with chronic administration, a tachyphylaxis pattern distinct from the sustained gastric effects seen with some GLP-1 monoagonists.
Glucagon Suppression
Tirzepatide suppresses postprandial glucagon secretion via GLP-1 receptor-mediated inhibition of pancreatic alpha cells, reducing hepatic glucose output and contributing to HbA1c lowering independent of its insulinotropic actions.
Adipose Tissue Remodelling
Body composition analyses from SURMOUNT trials indicate that the majority of weight loss with tirzepatide is attributable to fat mass, with relative preservation of lean mass compared to historical dietary restriction data. This composition-favourable profile is consistent with direct adipose GIP receptor effects and is an active area of mechanistic research.
Researched Effects
- Mean body-weight reduction of approximately 22.5% at 72 weeks in SURMOUNT-1 at the 15 mg dose, with a substantial proportion of participants achieving ≥25% reduction.
- Clinically meaningful HbA1c reductions of 2.0–2.5 percentage points in SURPASS trials, with high rates of target attainment in type 2 diabetes research populations.
- Significant improvements in fasting plasma glucose, postprandial glucose, and insulin sensitivity markers across multiple randomised trials.
- Reductions in systolic blood pressure (approximately 7–10 mmHg), triglycerides, and LDL-cholesterol observed in SURMOUNT and SURPASS programmes.
- Improvements in waist circumference and visceral adiposity indices, suggesting favourable adipose tissue redistribution in research participants.
- Emerging evidence of cardiovascular benefit in SELECT-like cardiovascular outcomes research, with weight loss magnitude correlating with event-rate reduction.
- Exploratory data suggesting improvements in liver fat fraction and NASH-relevant histological markers in early-phase hepatology trials.
- Preliminary research indicating beneficial effects on sleep apnoea severity indices, investigated in SURMOUNT-OSA.
Theoretical Research Protocols
- Dosage range
- Escalation from 2.5 mg/week (starting dose) through 5, 7.5, 10, 12.5, to 15 mg/week maintenance (doses as studied in SURMOUNT/SURPASS trials)
- Frequency
- Once weekly subcutaneous administration; consistent day-of-week dosing used in all clinical trials
- Duration
- 72-week primary endpoints in SURMOUNT trials; indefinite maintenance in approved clinical indications
- Administration routes
- Subcutaneous injection via prefilled autoinjector pen (the sole route studied in all registrational trials), Injection sites studied include the abdomen, thigh, and upper arm with equivalent pharmacokinetics
Safety Profile
Common side effects (research)
- Nausea — the most commonly reported adverse event, typically dose-dependent and most pronounced during dose-escalation phases; reported in approximately 17–25% of participants at higher doses in SURMOUNT trials
- Vomiting — reported in approximately 6–10% of participants, generally transient and manageable with dose-titration adjustments
- Diarrhoea — reported in approximately 12–17% of participants, typically mild to moderate in severity
- Constipation — reported in approximately 11–13% of participants, particularly during maintenance phases when gastric-emptying effects stabilise
- Injection-site reactions including erythema, bruising, or mild induration at the administration site
- Decreased appetite — reported universally and considered mechanistically related to therapeutic effect rather than an adverse event per se
- Fatigue and asthenia, particularly during dose-escalation periods
Rare risks
- Acute pancreatitis — a class-level risk for incretin-based therapies; a causal relationship remains unestablished but warrants vigilance and discontinuation if symptoms arise
- Cholelithiasis and acute cholecystitis — observed at increased rates with rapid weight loss; reported in SURMOUNT trials at low but measurable frequency
- Tachycardia — modest increases in resting heart rate (approximately 2–4 bpm) observed, consistent with GLP-1 receptor class effects
- Diabetic retinopathy complications — a class-level concern with rapid glycaemic improvement; relevant in participants with pre-existing retinopathy
- Thyroid C-cell neoplasia — a regulatory class warning based on rodent pharmacology; human clinical relevance has not been established in SURMOUNT or SURPASS follow-up data
- Hypoglycaemia — low risk as a monotherapy given glucose-dependency of mechanism, but elevated when combined with insulin or sulphonylureas
Contraindications
- Personal or family history of medullary thyroid carcinoma (regulatory class contraindication based on rodent carcinogenicity data)
- Multiple endocrine neoplasia syndrome type 2 (MEN2)
- Personal or family history of pancreatitis (relative contraindication; requires clinical assessment)
- Pregnancy and breast-feeding (no clinical safety data; weight loss during pregnancy not recommended)
- Severe gastrointestinal disease including gastroparesis (exacerbation risk due to gastric-emptying effects)
- Hypersensitivity to tirzepatide or any excipients of the licensed formulation
UK Regulatory Status
United Kingdom (MHRA): Tirzepatide (Mounjaro) is a licensed prescription-only medicine in the UK, approved by the MHRA for the treatment of type 2 diabetes mellitus in adults and for chronic weight management in adults with a BMI ≥30 kg/m² (or ≥27 kg/m² with weight-related comorbidities) in conjunction with a reduced-calorie diet and increased physical activity. It may only be legally supplied by or under the direction of a licensed UK prescriber. Obtaining tirzepatide outside of a legitimate clinical or prescribing pathway raises serious regulatory and safety concerns.
European Union (EMA): Tirzepatide (Mounjaro) received European Medicines Agency (EMA) marketing authorisation for type 2 diabetes in September 2023 and for chronic weight management in 2024. It is a prescription-only medicine across all EU member states, regulated under the standard centralised authorisation procedure.
Notes: The supply of tirzepatide in the UK outside of a licensed clinical context—including unlicensed grey-market procurement—contravenes the Human Medicines Regulations 2012. Research-grade tirzepatide for legitimate in vitro or preclinical research is distinct from the licensed medicine and is subject to separate procurement and governance requirements. The peptide is listed by WADA as a prohibited substance in competitive sport.
Related research resources
Key Research Studies
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
A 72-week, randomised, double-blind, placebo-controlled phase 3 trial enrolling 2,539 adults without type 2 diabetes. Participants assigned to 15 mg tirzepatide achieved a mean weight reduction of 22.5% from baseline versus 2.4% with placebo (treatment difference −20.1 percentage points). Approximately 91% of participants in the 15 mg group achieved ≥5% weight loss and 57% achieved ≥20% weight loss, results unprecedented in pharmacological weight-management trials at that time.
Read sourceSURMOUNT-2: Tirzepatide in Adults with Obesity and Type 2 Diabetes
A 72-week randomised controlled trial in 938 adults with both obesity and type 2 diabetes. The 15 mg dose produced mean weight reductions of 15.7% compared to 3.3% with placebo. HbA1c reductions of approximately 2.4 percentage points were observed, demonstrating that tirzepatide's weight-management efficacy is preserved in individuals with established type 2 diabetes, though attenuated relative to the non-diabetic population.
Read sourceSURPASS-2: Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes
A 40-week head-to-head randomised trial comparing tirzepatide (5, 10, and 15 mg) with semaglutide 1 mg in 1,879 adults with type 2 diabetes. All tirzepatide doses produced superior HbA1c reductions (−2.01%, −2.24%, −2.30% vs −1.86%) and greater weight loss (−7.6 kg, −9.3 kg, −11.2 kg vs −5.7 kg) compared to semaglutide, with a comparable overall adverse-event profile.
Read sourceSURMOUNT-4: Continued Tirzepatide versus Placebo after Weight-Loss Induction
A 52-week randomised withdrawal trial in which all participants first received open-label tirzepatide for 36 weeks before being randomised to continued tirzepatide or switch to placebo. Continued treatment produced a further 6.7% weight reduction, while placebo-switchers regained an average of 14.8% of body weight, providing strong evidence for the ongoing pharmacological contribution to weight maintenance.
Read sourceSURPASS-CVOT: Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes
An ongoing large-scale cardiovascular outcomes trial assessing the effect of tirzepatide on major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease. Interim and published data have demonstrated non-inferiority and exploratory superiority trends for MACE reduction, consistent with the cardiometabolic risk-factor improvements observed across the SURPASS programme.
Frequently Asked Questions
What is tirzepatide and how does it differ from older GLP-1 agonists?
Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates both the GIP and GLP-1 incretin receptors simultaneously, whereas older agents such as semaglutide or liraglutide act only on the GLP-1 receptor. This dual mechanism appears to produce substantially greater reductions in body weight and blood glucose than GLP-1 monoagonism alone, as demonstrated in the head-to-head SURPASS-2 trial and confirmed by the magnitude of weight loss in the SURMOUNT programme.
Is tirzepatide available in the UK?
Yes. Tirzepatide (Mounjaro) is an MHRA-licensed prescription medicine in the UK approved for type 2 diabetes management and chronic weight management. It is available through NHS prescribing pathways and private clinics. It is a prescription-only medicine and cannot legally be supplied without a valid UK prescription from a qualified prescriber. Research-grade tirzepatide is separately available for legitimate preclinical research under appropriate governance.
What weight loss has been observed with tirzepatide in clinical research?
In SURMOUNT-1, the pivotal 72-week randomised controlled trial in adults without type 2 diabetes, participants receiving the 15 mg maintenance dose achieved a mean weight reduction of approximately 22.5% from baseline. This is approximately twice the weight loss typically observed with semaglutide 2.4 mg (Wegovy) in comparable populations and represents the largest pharmacologically induced weight reduction reported in any registered clinical trial at the time of publication.
What are the most common side effects of tirzepatide in research populations?
In SURMOUNT and SURPASS trial populations, the most frequently reported adverse events were gastrointestinal in nature: nausea (reported by approximately 17–25% at higher doses), diarrhoea (12–17%), constipation (11–13%), and vomiting (6–10%). These effects are most pronounced during dose-escalation phases and typically attenuate with continued treatment. The slow titration schedule used in the trials is specifically designed to improve gastrointestinal tolerability.
How does tirzepatide's mechanism of action produce greater weight loss than GLP-1 monotherapy?
The enhanced efficacy is attributed to the combined and potentially synergistic activation of both GIP and GLP-1 receptors. GIP receptor activation in adipose tissue and the central nervous system adds appetite-suppressing and energy-partitioning effects that complement those of GLP-1 receptor agonism. Additionally, GIP receptor co-activation may sensitise adipose tissue to the lipolytic actions of GLP-1 signalling. The net result is a greater reduction in ad libitum energy intake and a more favourable fat-to-lean mass loss ratio than observed with GLP-1 monoagonists.
Are there cardiovascular benefits associated with tirzepatide research?
The SURPASS-CVOT trial and cardiometabolic biomarker data from SURMOUNT trials have demonstrated reductions in established cardiovascular risk markers including systolic blood pressure, triglycerides, LDL-cholesterol, and waist circumference. The SELECT trial framework applied to semaglutide established a precedent for pharmacological weight-management agents reducing hard cardiovascular events, and tirzepatide's SURPASS-CVOT data have shown consistent directional trends supporting cardiovascular risk reduction.
Is tirzepatide research exploring applications beyond diabetes and obesity?
Active clinical research is investigating tirzepatide in several additional contexts: SURMOUNT-OSA examined obstructive sleep apnoea severity; early-phase hepatology studies are assessing liver fat reduction and NASH histological improvement; and the SUMMIT trial is investigating its effects in heart failure with preserved ejection fraction. These exploratory programmes reflect the broad metabolic and organ-protective implications of dual incretin receptor agonism.
What is the regulatory status of tirzepatide for research purposes in the UK?
Tirzepatide is a licensed prescription medicine under the Human Medicines Regulations 2012. For legitimate preclinical or in vitro research, research-grade tirzepatide peptide may be procured through specialist research chemical suppliers subject to appropriate institutional governance. Its supply for unlicensed human use outside of a prescribing pathway is prohibited. Any research programme involving human participants requires full ethical approval and appropriate regulatory authorisation.
Licensed brand-name medicines
Related trials
Related mechanisms
Related conditions
Type 2 diabetes
Obesity
Prediabetes
Metabolic syndrome
MASLD / MASH (metabolic dysfunction-associated steatotic liver disease)
Obstructive sleep apnoea (OSA)
Heart failure with preserved ejection fraction (HFpEF)
Cardiovascular risk
Visceral adiposity
Sarcopenic obesity and lean-mass concerns
Post-weight-loss maintenance
Weight regain after GLP-1 discontinuation
Polycystic ovary syndrome (PCOS)